Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sodium iodide (123I)
- Development stage
- Approved
- Lead developer
- V.G. Khlopin Radium Institute
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
Sodium iodide (123I) is a diagnostic radiopharmaceutical developed by the Khlopin Radium Institute for the functional and anatomical assessment of the thyroid gland. It contains the radioisotope iodine-123, which emits gamma radiation suitable for scintigraphy and SPECT imaging. The iodide ion is actively sequestered from the bloodstream by thyroid follicular cells through the sodium-iodide symporter (NIS). This localization allows clinicians to measure iodine uptake rates and visualize thyroid topography to diagnose conditions such as thyrotoxicosis, nodular or diffuse goiters, and thyroid carcinomas. Its relatively short half-life of approximately 13.2 hours provides a favorable safety profile with lower radiation exposure compared to iodine-131, making it a preferred choice for diagnostic imaging and functional thyroid studies.
- Brand names
- Натрия йодид, 123I
- Other names
- 123I Sodium IodideSodium Iodide (123I)Sodium iodide-123
02
Targets
NIS (Human sodium iodide symporter)
Beyond the preview
Go deeper on sodium iodide (123I).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sodium iodide (123I).